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Abstract: Background. Recurrent Clostridium difficile infection
(CDI) represents a significant burden on the healthcare system and
is associated with poor outcomes in hematopoietic stem cell
transplant (HSCT) patients. Data are limited evaluating recurrence
rates and risk factors for recurrence in HSCT patients.
Methods. HSCT patients who developed CDI between January 2010
and December 2012 were divided into 2 groups: non-recurrent CDI
(nrCDI) and recurrent CDI (rCDI). Risk factors for rCDI were
compared between groups. Rate of recurrence in HSCT patients was
compared to that in other hospitalized patients.
Results. CDI was diagnosed in 95 of 711 HSCT patients (22 rCDI and
73 nrCDI). Recurrence rates were similar in HSCT patients
compared with other hospitalized patients (23.2% vs. 22.9%,
P > 0.99). Patients in the rCDI group developed the index case of
CDI significantly earlier than the nrCDI group (3.5 days vs. 7.0 days
after transplant, P = 0.05). On univariate analysis, patients with rCDI
were more likely to have prior history of CDI and neutropenia at the
time of the index CDI case. Neutropenia at the time of the index CDI
case was the only independent predictor of rCDI (78.8 vs. 34.8%,
P = 0.006) on multivariate analysis.
Conclusions. The rate of rCDI was similar between HSCT and other
hospitalized patients, and the majority of patients developed the
index case of CDI within a week of transplantation. Neutropenia at
the index CDI case may be associated with increased rates of rCDI.
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Clostridium difficile infection (CDI) is the leading cause
of nosocomial infectious diarrhea in the United States.
The incidence of CDI in patients undergoing hemato-
poietic stem cell transplantation (HSCT) is approxi-
mately 5–30% compared with 1–2% in the general
hospitalized population (1–4). HSCT patients are com-
monly exposed to risk factors for the development of
CDI, including prolonged length of hospitalization,
exposure to broad-spectrum antibiotics, receipt of
acid-suppression therapy, disrupted integrity of intesti-
nal mucosa, and profound immunosuppression (5).
Despite higher prevalence of CDI in HSCT recipients,
limited information is available evaluating recurrent
infection. In addition, risk factors for recurrent infection
in HSCT have not been thoroughly evaluated. There-
fore, the objective of this study was to determine the
incidence of recurrent CDI (rCDI) in HSCT patients
compared with that in the general hospitalized popula-
tion, and to examine risk factors for rCDI. Character-
ization of risk factors for rCDI may aid in identification
of patient populations that might benefit from preven-
tion strategies or targeted initial treatment.
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Patients and methods
This retrospective case–control study was conducted at
the University of Michigan Health System (UMHS) and
received investigational review board approval. Patients
were included if they underwent HSCT at UMHS
between January 2010 and December 2012 and devel-
oped CDI 7 days before HSCT through 1 year post
transplant. Patients were considered to have CDI if they
exhibited symptoms consistent with CDI and had a
stool sample test positive for C. difficile in the UMHS
Clinical Microbiology Laboratory. Stool testing was
performed using the C. DIFF QUIK CHEK COM-
PLETE test (Alere/TECHLAB, Inc.; Blacksburg,
Virginia, USA) for C. difficile glutamate dehydrogenase
antigen and toxins A or B by enzyme immunoassay. All
glutamate dehydrogenase-positive/toxin-negative stool
tests were subjected to analysis for the tcdB gene by
real-time polymerase chain-reaction assay (BD Gene-
OhmTM Cdiff Assay; Franklin Lakes, New Jersey, USA).
Pediatric patients <2 years of age were excluded. For
patients who received >1 HSCT in a calendar year, only
the first transplant was evaluated.
The study population was divided into 2 groups for
analysis: rCDI and non-recurrent CDI (nrCDI); rCDI
was defined as a repeat positive CDI occurring within
6 months after the end of treatment for the index
case (first episode of CDI after transplantation). To
compare rates of rCDI in general hospitalized popu-
lation with those in HSCT patients, incidence of rCDI
was also estimated for all hospitalized patients
between January 2010 and December 2012. Patients
who received an HSCT in the year before diagnosis
of the index episode of CDI were excluded from
this group; thus no patients were included in both
groups.
Data collection points included patient demograph-
ics, CDI severity and complications, CDI treatment,
traditional CDI risk factors for recurrence, potential
HSCT-specific risk factors for recurrence, and timing
and frequency of rCDI. Traditional risk factors for
recurrence include age >65 years, broad-spectrum
antibiotics, acid-suppression therapy, history of CDI,
and hospitalization ≥14 days. History of CDI was
defined as CDI in the year before transplantation and
occurring before the index episode. Additional HSCT-
related factors were also collected and analyzed as
potential predictors for recurrent disease including type
of transplant (autologous vs. allogeneic [autoHSCT vs.
alloHSCT]), alloHSCT from a matched related or
unrelated donor, myeloablative conditioning regimen,
neutropenia at the time of the index case (defined as an
absolute neutrophil count <500 cells/mm3), the index
CDI case occurring during hospitalization for trans-
plantation, use of prophylactic immunosuppressive
medications, use of immunosuppression for treatment
of graft-versus-host disease (GVHD), diagnosis of
biopsy-proven cytomegalovirus colitis, and diagnosis
of GVHD. All risk factors were collected from the day of
positive CDI result to the end of the CDI treatment
course. All patients transplanted at UMHS were fol-
lowed by our transplant team for both inpatient and
outpatient care.
Severe CDI was defined as an episode of CDI
resulting in need for intensive care unit admission,
interventional surgery, or death within 30 days of CDI
diagnosis (6). GVHD grading according to Glucksberg
criteria (7) was captured for each alloHSCT patient and
recorded in a transplant database. GVHD was further
categorized as acute (onset ≤100 days post transplant)
or chronic (onset >100 days post transplant). Patients
who received tumor necrosis factor-alpha inhibitors or
rituximab for the treatment of GVHD within 90 days
before CDI onset were considered to be on immuno-
suppression because of the prolonged immunosuppres-
sive effect of these agents.
Statistical analysis
All statistical analyses were performed using SPSS
Software Version 20.0 (SPSS, Inc., Chicago, Illinois,
USA). Demographic data were analyzed by descriptive
statistics, categorical data were analyzed by 2-tailed
Student t-test, and dichotomous data were analyzed by
Pearson chi-square test. Mann–Whitney U-tests were
performed for non-normally distributed factors.
Unconditional logistic regression analysis was per-
formed to evaluate factors associated with rCDI at the
time of the index CDI, and included traditional and
HSCT-related factors. Factors with P-value ≤0.2 on the
bivariate model were included in a multivariate uncon-
ditional logistic regression analysis. In the final model,
a P-value ≤0.05 (2-tailed) was considered statistically
significant. An additional bivariate sub-analysis, evalu-
ating alloHSCT and autoHSCT recipients, was per-
formed to determine if risk factors for recurrence differ
between these 2 populations. Several variables, includ-
ing immunosuppression, GVHD, and treatment of
GVHD, were not applicable to autoHSCT patients and
were therefore not included in the analysis for that
population. No multivariable regression analysis was
performed in the subgroups owing to small sample
sizes.
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Results
CDI was diagnosed in 95 of 711 HSCT patients (13.4%)
from January 2010 to December 2012, which included
330 alloHSCTs and 381 autoHSCTs. The overall
incidence of CDI was 18.2% (60 of 330 patients) in
alloHSCT recipients and 9.2% (35 of 381 patients) in
autoHSCT recipients, P < 0.001 (Fig. 1). CDI rate in
the HSCT population during the study period was
approximately 1.75 per 10,000 patient days. The aver-
age age of the whole cohort was 45 years and 53.7%
were male.
RCDI occurred in 22 patients, and the incidence of
rCDI did not differ between alloHSCT and autoHSCT
recipients (23.3% vs. 22.9%, P > 0.99). When compared
with all inpatients during the same time period, the
recurrence rate was not significantly higher in HSCT
patients (18.5% vs. 23.2%, P = 0.283). In the rCDI group,
16 patients had 1 episode of recurrence (72.7%), 4
patients experienced 2 recurrences (18.2%), and 2
patients had 3 recurrences (9.1%). Among rCDI
patients, 31.8% developed recurrence <4 weeks after
the end of treatment for their index case, 45.5% at 4–
12 weeks, and 22.7% at >12 weeks (Fig. 2).
Age, gender, and incidence of severe CDI did not
significantly differ between the rCDI and nrCDI groups
(Table 1). Overall, the majority of patients developed
their index case of CDI during day 7 to day +14 post
transplant (Fig. 3). Patients in the rCDI group devel-
oped their index case of CDI significantly earlier than
patients in the nrCDI group (3.5 days vs. 7.0 days,
P = 0.05). All patients in the rCDI group and 95.9% of
patients in the nrCDI group received oral metronida-
zole for at least part of their CDI treatment, and a
proportion were switched to oral vancomycin or initi-
ated on combination therapy at some time during their
treatment course. One patient in the nrCDI group
received vancomycin rectal enemas. No significant
differences were seen between the 2 groups with
regard to CDI antimicrobial treatment choice or dura-
tion of therapy (Table 2).
Traditional risk factors for recurrence and HSCT-
related factors were compared between the rCDI and
nrCDI groups via bivariate analysis. Among traditional
risk factors for recurrence, history of CDI in the year
before transplantation was seen frequently in the rCDI
population (22.7% vs. 6.8%, P = 0.048), but acid-sup-
pression therapy, broad-spectrum antibiotic use, and
hospital stay ≥14 days were not significantly different
between the 2 groups. Analysis of HSCT-related factors
revealed significantly more patients in the rCDI group
were neutropenic during their index case of CDI (59.1%
vs. 28.8%, P = 0.012). No other HSCT-related factors
were statistically significantly different between the
rCDI and nrCDI groups.
Neutropenia at the time of the index case was found
to be the only independent predictor of recurrent
Fig. 1. Study population. HSCTs, hematopoietic stem cell trans-
plants; CDI, Clostridium difficile infection; r, recurrent; nr, non-
recurrent.
Fig. 2. Timing of recurrence in recurrent Clostridium difficile infec-
tion (rCDI) patients.
Fig. 3. Timing of initial Clostridium difficile infection (CDI) episode
with relation to transplant date; nr, non-recurrent; r, recurrent.
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Baseline demographics
Recurrent (rCDI)
(n = 22) Non-recurrent (nrCDI) (n = 73) P-value
Demographics
Age at index case (mean  SD) 41.46  20.9 45.5  21.3 0.460
Male 11 (50.0) 40 (54.8) 0.808
Severe CDI 3 (13.6) 5 (6.8) 0.820
Traditional risk factors for recurrence
Age >65 1 (4.6) 7 (9.6) 0.677
History of CDI 5 (22.7) 5 (6.8) 0.048
Hospitalization ≥14 days 22 (100.0) 70 (95.9) >0.99
Acid-suppression therapy
PPI 9 (40.9) 44 (60.3) 0.143
H2RA 9 (40.9) 19 (26.0) 0.193
Broad-spectrum antibiotics
Carbapenems 2 (9.1) 1 (1.4) 0.133
Cephalosporins 14 (63.6) 32 (43.8) 0.144
Clindamycin 1 (4.6) 0 (0.0) 0.232
Fluoroquinolones 11 (50.0) 24 (32.9) 0.207
BL/BLIs 3 (13.6) 19 (26.0) 0.266
Other1 7 (31.8) 16 (21.9) 0.398
HSCT-related factors
Index case during hospitalization for HSCT 18 (81.8) 48 (65.8) 0.192
Neutropenic (ANC <500) at index case 13 (59.1) 21 (28.8) 0.012
Type of transplant
Allogeneic 14 (63.6) 46 (63.0) >0.99
Matched (% of allogeneic HSCTs) 12 (85.7) 41 (89.1) 0.661
Conditioning regimen
Myeloablative 19 (86.4) 58 (79.5) 0.552
Immunosuppression (prophylaxis) 13 (59.1) 43 (58.9)
Tacrolimus 12 (54.5) 40 (54.8) >0.99
Mycophenolate 6 (27.3) 16 (21.9) 0.578
Cyclosporine 0 (0.0) 2 (2.7) >0.99
Methotrexate 5 (22.7) 22 (30.1) 0.597
Other2 7 (31.8) 23 (31.57) >0.99
Immunosuppression (treatment for GVHD)
High-dose steroids (>0.5 mg/kg prednisone equivalent) 1 (4.5) 10 (13.7) 0.448
TNF-alpha inhibitor 0 (0.0) 2 (2.7) >0.99
Rituximab 0 (0.0) 1 (1.4) >0.99
Other3 0 (0.0) 5 (6.8) 0.587
CMV colitis 0 (0.0) 2 (2.7) >0.99
GVHD
Acute 1 (4.5) 7 (9.6) 0.677
Chronic 1 (4.5) 4 (5.5) >0.99
1Other broad spectrum antibiotics: vancomycin, aztreonam.
2Other immunosuppression (prophylaxis): vorinostat, sirolimus, etanercept, extracorporeal photopheresis.
3Other immunosuppression (treatment for GVHD): alemtuzemab, cyclosporine, budesonide.
CDI, Clostridium difficile infection; SD, standard deviation; PPI, proton pump inhibitor; H2RA, histamine-2 receptor antagonist; BL/BLI, b-lactam/
b-lactamase inhibitor; HSCT, hematopoietic stem cell transplantation; ANC, absolute neutrophil count; GVHD, graft-versus-host disease; TNF,
tumor necrosis factor; CMV, cytomegalovirus.
Table 1
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disease (odds ratio [OR] 3.64, 95% confidence interval
[CI] 1.09–12.16, P = 0.040) on multivariate analysis.
Multiple known risk factors for recurrence in the
general population appeared to predict recurrence of
CDI in HSCT patients on bivariate analysis; however,
these differences did not remain significant on multi-
variable regression analysis (Table 3).
In bivariate analysis in alloHSCT patients, neutrope-
nia at the time of the index case was significantly
higher in the rCDI group vs. the nrCDI group (78.8%
vs. 34.8%, P = 0.006). Among autoHSCT patients, more
patients in the rCDI group had previous history of CDI
(25% vs. 0%, P = 0.047). The association between
neutropenia at the time of the index case and rCDI
was not statistically significant in autoHSCT patients.
No other variables were significantly different between
the 2 groups in either transplant population.
Discussion
CDI represents a significant complication in HSCT
patients. Recent studies have reported a direct corre-
lation between early CDI and development of gastroin-
testinal (GI) tract GVHD with subsequent increases in
mortality (8, 9). GVHD represents an important factor
associated with overall transplant outcomes, and min-
imizing the development of GVHD is imperative.
Identification of risk factors for recurrence early during
the transplant course may allow for utilization of
preventative strategies or targeted CDI treatment
during the index episode, potentially minimizing the
risk of recurrent infection and HSCT-related complica-
tions.
The current literature describing rCDI rates in HSCT
recipients or risk factors for rCDI in the population is
limited. Previously published studies include one
retrospective nested case–control study conducted by
Alonso et al. (4) in autoHSCT and alloHSCT analyzing
risk factors for CDI. In a subanalysis, this group found
that GI GVHD conferred a nearly 5-fold higher risk for
CDI recurrence after controlling for confounders
(adjusted OR, 4.23 [95% CI, 1.20–14.86]; P = 0.02). This
was a novel finding and further suggests a relationship
between CDI and GVHD. However, this study did not
account for several other well-known risk factors for
rCDI including history of CDI or antibiotic use during
CDI, which may have contributed to CDI recurrence.
Timing of onset of infection was also not captured.
To our knowledge, this study is the first to directly
examine factors associated with rCDI in the HSCT
population, including both traditional risk factors for
recurrence as well as potential HSCT-related factors.
We observed a 23.3% recurrence rate, which is similar
to that seen in a prior study in HSCT patients (21.7%)
(5). In addition, we observed high rates of early initial
CDI in our cohort irrespective of subsequent recur-
rence, specifically in the first 7 days post transplant.
Based on the results of our multivariate analysis, it
appears that traditional risk factors for recurrence in
the general hospitalized population may not be as
strongly associated with rCDI in HSCT patients as
other variables. Although a significant correlation was
seen between recurrent infection and a prior history of
CDI on bivariate analysis, this association became non-
significant after accounting for other covariates. This
finding may be a result of the fact that most transplant
patients display many traditional risk factors for recur-
rence including use of broad-spectrum antibiotics and
acid-suppression therapy, as part of UMHS transplant
protocols.
The strongest predictor of recurrent disease for the
cumulative population, based on our regression model,
was neutropenia at the time of the index CDI episode.
Reasons for this finding are currently not well defined.
Colitis due to CDI is a neutrophilic process, and the
extent to which neutrophils are required for clearance
of infecting clostridia or pathophysiology of the disease
is unclear. A previous case–control study in HSCT
patients found that receipt of growth factor was
associated with a reduced risk of rCDI (10). These







(n = 73) P-value
Time to index CDI
case (median, IQR)
3.5 (0.25–6.0) 7.0 (2.0–33.0) 0.050
CDI treatment
(index case)1
Metronidazole (po) 22 (100.0) 70 (95.9) >0.99
Vancomycin (po) 5 (22.7) 24 (32.9) 0.437
Combination2 2 (9.1) 9 (12.3) >0.99
Other3 0 (0.0) 1 (1.4) >0.99
Duration of CDI
treatment (index case)
≤14 days 9 (40.9) 29 (39.7) >0.99
1Received at least 1 dose of the agent.
2Combination treatments: vancomycin (po) and metronidazole (IV).
3Other treatments: vancomycin rectal enemas.
IQR, interquartile range; po, oral; IV, intravenous.
Table 2
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data, in addition to our findings, are consistent with
neutrophils being important for the elimination of
C. difficile from the GI tract, but this is an area for
future research.
It is also possible that neutropenia in our study was a
surrogate marker of a lack of memory cell response to
past infection, or infection that occurred before engraft-
ment. In a prospective study of 63 patients with
nosocomial CDI, serial serum immunoglobulin (Ig)A,
IgG, and IgM concentrations against CDI toxins A and B
were measured and followed up for relapsed infection.
Based on multivariate logistic regression analysis, the
authors found that serum antibody response to toxin A
during the initial episode of CDI was associated with
protection against recurrence (10). In addition, a statis-
tically significant downward trend in recurrence rates
was observed with increasing serum IgM concentra-
tions against CDI toxin A, measured on day 3 of initial
infection. Several other small studies analyzing the
relationship between serum Ig levels and rCDI have
reached similar conclusions (11–13). Thus, it could be
speculated that leukopenic HSCT recipients might be
unable to mount appropriate immune responses during
the initial CDI episode, and may therefore be at higher
risk of recurrent infection.
Similarly, disruption of the integrity of the GI mucosa
by the conditioning regimen, which is most profound
during the pre-engraftment period, could also play a
role in recurrent infection. Studies have shown that
chemotherapy-induced mucositis alters the composi-
tion of the intestinal microflora, causes reduction in
epithelial repair, and impairs normal functions such as
immune regulation and protection from pathogen
overpopulation (3, 14, 15). C. difficile spores may thus
be more adept to survive, proliferate, and cause
recurrence in patients with severely suppressed intes-
tinal micobiota (16). A secondary finding in our study
was that HSCT recipients with rCDI develop their index
case significantly earlier than nrCDI patients. This
correlates with our finding that neutropenia predicts
recurrence and supports the association between
immune deficiency and relapsed CDI.
Several limitations to this study should be noted. The
retrospective nature of our study makes it difficult to
account for all possible confounders that may impact
recurrence. However, by performing a multivariable
logistic regression, we accounted for traditional risk
factors for recurrence as well as potential transplant-
related factors. Our retrospective study was also limited
by our inability to accurately differentiate colonization
from infection in all patients owing to inconsistencies in
documentation of stool number and consistency. To
minimize treatment of colonized patients, our clinical
laboratory will not test solid stool for C. difficile and
Bivariate and multivariable unconditional logistic regression of factors present at index case that predict recurrent infection
Bivariate analysis1 Multivariate logistic regression
Factors
Recurrent (rCDI)
(n = 22) Non-recurrent (nrCDI) (n = 73) P-value OR 95% CI P-value
Traditional risk factors
History of CDI 5 (22.7) 5 (6.8) 0.048 3.55 0.78–16.11 0.101
Acid-suppression therapy
PPI 9 (40.9) 44 (60.3) 0.143 0.40 0.09–1.90 0.254
H2RA 9 (40.9) 19 (26.0) 0.193 0.86 0.17–4.42 0.855
Broad-spectrum antibiotics
Carbapenems 2 (9.1) 1 (1.4) 0.133 8.13 0.50–133.05 0.142
Cephalosporins 14 (63.6) 32 (43.8) 0.144 1.66 0.54–5.13 0.382
HSCT-related factors
Index case during hospitalization for HSCT 18 (81.8) 48 (65.8) 0.192 1.15 0.27–4.85 0.849
Neutropenic (ANC <500) at index case 13 (59.1) 21 (28.8) 0.012 3.64 1.09–12.16 0.040
1All known risk factors for rCDI and potential risk factors for rCDI as defined in Table 1 were included in the bivariate analysis and all covariates
with a P < 0.20 are listed in the table.
rCDI, recurrent Clostridium difficile infection; nrCID, non-recurrent Clostridium difficile infection; OR, odds ratio; CI, confidence interval; PPI,
proton-pump inhibitors; H2RA, histamine-2 receptor antagonist; HSCT, hematopoietic stem cell transplantation; ANC, absolute neutrophil count.
Table 3
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institutional policy recommends avoiding testing in
patients with a single episode of diarrhea or for test-of-
cure. In addition, our study may have been underpow-
ered to detect a difference in rare events, such as
cytomegalovirus colitis or GVHD, as a predictor of rCDI.
In contrast to Alonso et al. (4), we did not find a higher
rate of rCDI in patients with GI GVHD, despite having a
similar sample size. The overall rate of GVHD does not
appear to be higher at UMHS compared with other
institutions with similar HSCT populations, thus other
factors, such as differences in antimicrobial stewardship
practice or infection control measures at our institution,
may have impacted differences seen in incidence of
rCDI. It is possible that, with a larger sample size, these
factors may also predict recurrence. Finally, data for
biomarkers, such as creatinine, albumin, or inflamma-
tory markers, that have been shown to be associated
with rCDI, would have been ideal to account for in our
analysis; however, this information was not collected for
all patients and thus was not included.
The results of our study indicate that the rate of rCDI
in HSCT recipients is similar to that in non-HSCT
hospitalized patients. However, traditional risk factors
of recurrent infection do not appear to predict relapse in
this population. While we did not observe a relationship
between GI GVHD and recurrent disease, we saw a
significant association with patients who were neu-
tropenic at the time of the index episode of CDI,
possibly related to a lack of memory response to the
initial insult. In addition, we observed that patients with
rCDI developed their index episode early in the post-
transplant period. This finding most likely correlates
with timing of neutropenia and highlights the potential
need for preventative measures before or early after
transplantation. Identifying risk factors for rCDI in the
HSCT population has important implications regarding
the initial management of CDI episodes. Novel treat-
ment modalities or prevention strategies, such as pre-
transplant screening and decolonization, use of prophy-
laxis, longer duration of therapy, and pulse-dose or
long-term taper antibiotic therapy, could be potential
methods to minimize recurrent infection in high-risk
patients. Further studies should be conducted to
evaluate if targeted therapy or pre-engraftment prophy-
laxis should be considered in HSCT recipients with
certain risk factors for recurrence.
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